H2S donor GYY4137 mitigates sFlt-1-induced hypertension and vascular dysfunction in pregnant rats
Biology of Reproduction · 14.10.2024 · 111 (4) · 879-889
DOI: 10.1093/biolre/ioae103 ↗Kurz gefasst
Fachartikel in der Zeitschrift Biology of Reproduction, online erschienen am 28.06.2024. Verfasst von Pankaj Yadav und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Comparative Biosciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI, USA. Hauptthemen laut MEDLINE: Hydrogen Sulfide, Morpholines, Organothiophosphorus Compounds, Vascular Endothelial Growth Factor Receptor-1. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIEHS NIH HHS, NICHD NIH HHS, NIH HHS.
Abstract (Originalsprache)
Gestational hypertension, often associated with elevated soluble Fms-related receptor tyrosine kinase 1 (sFlt-1), poses significant risks to both maternal and fetal health. Hydrogen sulfide (H2S), a gasotransmitter, has demonstrated blood pressure-lowering effects in hypertensive animals and humans. However, its role in pregnancy-induced hypertension remains unclear. This study investigated the impact of GYY4137, a slow-release H2S donor, on sFlt-1-induced hypertension in pregnant rats . Pregnant rats were administered sFlt-1 (6 μg/kg/day, intravenously) or vehicle from gestation day (GD) 12–20. A subset of these groups received GYY4137 ( 50 mg/kg/day, intraperitoneal) from GD 16–20. Serum H2S levels, mean arterial blood pressure, uterine artery blood flow, and vascular reactivity were assessed. Elevated sFlt-1 reduced both maternal weight gain and serum H2S levels. GYY4137 treatment restored both weight gain and H2S levels in sFlt-1 dams. sFlt-1 increased mean arterial pressure and decreased uterine artery blood flow in pregnant rats. However, treatment with GYY4137 normalized blood pressure and restored uterine blood flow in sFlt-1 dams. sFlt-1 dams exhibited heightened vasoconstriction to phenylephrine and GYY4137 significantly mitigated the exaggerated vascular contraction. Notably, sFlt-1 impaired endothelium-dependent relaxation, while GYY4137 attenuated this impairment by upregulating eNOS protein levels and enhancing vasorelaxation in uterine arteries. GYY4137 mitigated sFlt-1-induced fetal growth restriction. In conclusion, sFlt-1 mediated hypertension is associated with decreased H2S levels. Replenishing H2S with the donor GYY4137 mitigates hypertension and improves vascular function and fetal growth outcomes. This suggests modulation of H2S could offer a novel therapeutic strategy for managing gestational hypertension and adverse fetal effects.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Comparative Biosciences, School of Veterinary Medicine, University of Wisconsin, Madison, WI, USA.
- Department of Obstetrics and Gynecology, University of California, Irvine, CA, USA.
- Department of Obstetrics and Gynecology, School of Medicine and Public Health, University of Wisconsin, Madison, WI, USA.
Förderung
- NIEHS NIH HHS
- NICHD NIH HHS
- NIH HHS
- National Institutes of Health
Zitieren
APA
Yadav, P., Mishra, J. S., Hurt, M. W., Chen, D. B., & Kumar, S. (2024). H2S donor GYY4137 mitigates sFlt-1-induced hypertension and vascular dysfunction in pregnant rats. Biology of Reproduction, 111(4), 879-889. https://doi.org/10.1093/biolre/ioae103
Vancouver
Yadav P, Mishra JS, Hurt MW, Chen DB, Kumar S. H2S donor GYY4137 mitigates sFlt-1-induced hypertension and vascular dysfunction in pregnant rats. Biology of Reproduction. 2024;111(4):879-889. doi:10.1093/biolre/ioae103
BibTeX
@article{Yadav2024,
author = {Yadav, Pankaj and Mishra, Jay S and Hurt, Mason William and Chen, Dong-Bao and Kumar, Sathish},
title = {H2S donor GYY4137 mitigates sFlt-1-induced hypertension and vascular dysfunction in pregnant rats},
journal = {Biology of Reproduction},
year = {2024},
volume = {111},
number = {4},
pages = {879--889},
doi = {10.1093/biolre/ioae103}
}
EUVIMED